Diphtheria Global Market Report 2024

The global diphtheria market has grown strongly in recent years. It will grow from $8.34 billion in 2023 to $8.91 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to vaccine development, immunization campaigns, increased awareness, healthcare infrastructure.

The global diphtheria market is expected to see strong growth in the next few years. It will grow to $11.51 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to emerging outbreaks, booster vaccination programs, global travel and migration, public health preparedness. Major trends in the forecast period include combination vaccines, telemedicine for vaccination, vaccine equity initiatives, public-private partnerships.

The diphtheria market is poised for growth, buoyed by the increasing prevalence of bacterial infections. Bacterial infections refer to diseases or conditions arising from bacterial overgrowth or the toxins produced by invading bacteria in the body. Diphtheria, a severe infection triggered by specific bacterial strains that suppress the immune system and facilitate the proliferation of Corynebacterium diphtheriae, is a pertinent concern. For instance, a report from the European Centre for Disease Prevention and Control in November 2022 highlighted a doubling in reported infections of Acinetobacter species resistant to multiple antimicrobial groups in 2021, and more than 35,000 individuals succumb to antimicrobial-resistant infections annually in the EU. Furthermore, the number of cases of Klebsiella pneumonia surged by 31% in 2020 and an additional 20% in 2021. As such, the escalating incidence of bacterial infections is poised to be a driving force behind the diphtheria market's expansion.

The diphtheria market is experiencing growth, largely underpinned by the upward trajectory of immunization programs. Immunization programs encompass a suite of services aimed at safeguarding individuals against vaccine-preventable illnesses by delivering vaccinations. These programs are designed to curtail sickness, disability, and mortality stemming from vaccine-preventable maladies. Diphtheria and other vaccines are routinely administered to individuals through immunization initiatives spanning different countries and regions. For instance, in July 2023, the United Nations International Children's Emergency Fund (UNICEF) reported an uptick in global coverage for the third dose of the Diphtheria, Tetanus, Pertussis (DTP3) vaccination. This coverage increased from 81% in 2021 to 84% in 2022 through immunization efforts. Consequently, the escalating prominence of immunization programs is a propellant behind the growth of the diphtheria market.

The diphtheria market's growth is significantly hindered by vaccine side effects, particularly type A immune reactions. These side effects present a notable challenge to the diphtheria market during the forecast period. Type A immune reactions, although uncommon, represent a severe adverse outcome of immunizations, notably diphtheria vaccines. These responses manifest with the onset of symptoms such as fever, malaise, myalgia, headaches, and chills within hours after vaccination. Type A immunological responses can potentially lead to fatalities and necessitate immediate medical attention. In May 2022, the U.S. Department of Health and Human Services reported serious vaccine side effects, which included symptoms like tachycardia, widespread rashes, breathing difficulties, dizziness, and weakness. Thus, the presence of side effects, such as type A immune reactions, acts as a significant impediment to the diphtheria market's progress.

Companies engaged in the diphtheria market are actively innovating and securing FDA approvals to maintain their market positions. A prime example of such innovation occurred in October 2022 when GlaxoSmithKline PLC, a U.K.-based pharmaceutical and biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) granted approval for BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, adsorbed; Tdap). This approval permits immunization during the third trimester of pregnancy to prevent pertussis (whooping cough) in infants under two months old. Administering the Tdap vaccine to pregnant women confers optimal protection against whooping cough for newborns during their initial months of life through the transference of protective antibodies from mother to child.

In December 2022, Pharmaniaga LifeScience Sdn Bhd (PLS), a pharmaceutical company headquartered in Malaysia, initiated a collaborative research agreement with BioNet-Asia Co. Ltd. (BioNet) for an undisclosed sum. This partnership focuses on the research and development of a 6-in-1 Hexavalent Vaccine targeting diseases like diphtheria (DT), tetanus (TT), pertussis (aP), poliomyelitis (IPV), Haemophilus influenzae type b (Hib), and hepatitis B (Hep-B). The collaboration is in line with Pharmaniaga's objective to establish the world's first Halal vaccine and insulin manufacturing facilities. This initiative aims to reduce Malaysia's reliance on imported life-saving vaccines and insulin, fostering the nation's goal of vaccine self-sufficiency. BioNet-Asia Co. Ltd. is a Thailand-based company specializing in the development and manufacturing of life-saving vaccines against bacterial infections, including diphtheria and tetanus.

Major players in the diphtheria market are Pfizer Inc., Johnson & Johnson Co, Roche Holding AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Serum Institute of India, Novavax Inc., Sinovac Biotech Ltd., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Bharat Biotech International Limited, CureVac AG, Inovio Pharmaceuticals Inc., The Native Antigen Company.

Asia-Pacific was the largest region in the diphtheria market in 2023. The regions covered in diphtheria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diphtheria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of infections related to diphtheria encompass diphtheria, skin diphtheria, and others. Diphtheria is a dangerous bacterial infection that can affect the tonsils, nose, throat, and/or skin and is caused by toxin-producing Corynebacterium diphtheriae bacteria. Diagnosis typically involves a physical examination and throat culture and can be confirmed with the use of antibiotics, antitoxins, and other treatment approaches. Diphtheria-related products and treatments are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies. These products and therapies are employed in a range of healthcare settings, including hospitals, homecare, specialty clinics, and others.

This report provides diphtheria market statistics, including diphtheria industry global market size, regional shares, competitors with a diphtheria market share, detailed diphtheria market segments, market trends and opportunities and any further data you may need to thrive in the diphtheria industry. This diphtheria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diphtheria market consists of revenues earned by entities by providing services such as consultation, diagnosis and treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The diphtheria market also includes the sales of medications such as vaccines, antibiotics and antitoxins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.